{
  "id": 1754,
  "text": "As shown by Bloss et al.1640, the addition of bleomycin in the cisplatin/ifosfamide doublet did not improve outcome in terms of response rates, PFS and OS in patients with histologically confirmed, advanced (FIGO stage IVB), recurrent, or persistent squamous cell carcinoma of the cervix not suitable for curative treatment with surgery and/or radiotherapy.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: As shown by Bloss et al.1640, the addition of bleomycin in the cisplatin/ifosfamide doublet did not improve outcome in terms of response rates, PFS and OS in patients with histologically confirmed, advanced (FIGO stage IVB), recurrent, or persistent squamous cell carcinoma of the cervix not suitable for curative treatment with surgery and/or radiotherapy.\n\n<question>: ",
  "ChatGPT_response_0": "根據研究顯示，在具體情境中，對於子宮頸鱗狀細胞癌患者，相較於使用cisplatin/ifosfamide的組合療法中添加bleomycin，結果顯示添加bleomycin並未在患者的反應率、無疾病進展生存期（PFS）和整體生存期（OS）方面改善。根據研究結果，使用cisplatin/ifosfamide的組合療法可能是更好的選擇。",
  "query": "在具體情境中，有什麼治療方法對於子宮頸鱗狀細胞癌患者的治療效果有較好的提升，相較於使用cisplatin/ifosfamide的組合療法中添加bleomycin呢？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在具體情境中，有什麼治療方法對於子宮頸鱗狀細胞癌患者的治療效果有較好的提升，相較於使用cisplatin/ifosfamide的組合療法中添加bleomycin呢？\n\n<reference text>: As shown by Bloss et al.1640, the addition of bleomycin in the cisplatin/ifosfamide doublet did not improve outcome in terms of response rates, PFS and OS in patients with histologically confirmed, advanced (FIGO stage IVB), recurrent, or persistent squamous cell carcinoma of the cervix not suitable for curative treatment with surgery and/or radiotherapy.\n\n<reply>: ",
  "response": "根據研究顯示，在具體情境中，對於子宮頸鱗狀細胞癌患者，相較於使用cisplatin/ifosfamide的組合療法中添加bleomycin，結果顯示添加bleomycin並未在患者的反應率、無疾病進展生存期（PFS）和整體生存期（OS）方面改善。根據研究結果，使用cisplatin/ifosfamide的組合療法可能是更好的選擇。"
}